Merck

On an ordinary day over the last month of trading, MRK has moved about 1.85%, making it about as volatile as most of the stocks Kinzan tracks (their median is 1.81%).

Measured against its own habit, today is a −0.7σ day: the kind of session it has most weeks.

It sits in the lower half of its 24-hour range of 143.92–148.16, measured on hourly closes.

The London block (07:00–13:00 UTC) did most of the work — roughly 68% of the movement over the last 24 hours.

Over the last 60 sessions of daily returns, it has moved most closely with PFE (+0.65, a strong relationship), and most inversely to US30Y (−0.41).

Its last close is at the 89th percentile of its own last 82 sessions, and its 20-day volatility at the 55th.

Market read: Merck is sliding toward its 24h low, hit by heavy selling during the London session.

What it is

There are two Mercks, and they are unrelated businesses. This one is the American company based in New Jersey, which trades as MSD outside the United States and Canada; the German Merck KGaA of Darmstadt is a separate listed group. The American company’s largest franchise is oncology, led by Keytruda, an immunotherapy that helps the body’s immune system attack tumours and has been approved across a long list of cancer types. It also has a substantial vaccines business covering human papillomavirus, childhood immunisations and pneumococcal disease, along with hospital and cardiovascular medicines, and an animal-health division that sells treatments for livestock and pets.

What drives it

Concentration is the defining issue. A large share of revenue comes from a single cancer medicine whose key US patent protection expires later this decade, and the market’s view of the shares is largely a view of what happens afterwards. Three things feed that view: how much of the franchise can be retained through new formulations and combinations, how quickly the pipeline produces replacements, and what the company buys. Acquisitions are therefore read as strategic events, judged on price as much as on science. Vaccine sales have proved volatile in particular markets, for reasons that have little to do with the product. US drug-price negotiation under Medicare caps what older medicines can earn. Animal health, which is far less exposed to patent expiries, gives a steadier base underneath.

How it trades through the day

Results come before the US open. Clinical data is a larger source of movement than in most large drugmakers, and much of it is presented at oncology congresses such as the ASCO meeting in late spring and the European ESMO meeting in the autumn, with abstracts sometimes released before the presentations. The cash session runs 13:30 to 20:00 UTC from March to early November and 14:30 to 21:00 UTC in the remaining months. It is a Dow Jones Industrial Average constituent.

What it tends to move with

Bristol Myers Squibb, which sells a competing immunotherapy, is its most direct comparison in oncology, and AstraZeneca and Roche give an earlier read during European hours. It trades with Pfizer, Johnson & Johnson and the healthcare sector more broadly, and shares the sector’s defensive character on days when the index falls.